Abstract
Objectives
Radioactive iodine therapy is considered for patients with certain clinicopathological factors that predict a significant risk of recurrence, distant metastases of thyroid cancer or disease-specific mortality. The aim of the study was to investigate the association between polymorphisms of genes, products of which are involved in the processes of DNA damage response and autophagy, and the adverse reactions of radioiodine therapy in thyroid cancer patients.
Methods
The study included 181 patients (37 men, 144 women; median age 56 [41; 66.3] years) with histologically confirmed thyroid cancer and a history of thyroidectomy who received radioiodine therapy. NFKB1, ATM, ATG16L2, ATG10, TGFB1, and TNF polymorphisms were determined by allele-specific realtime-PCR.
Results
The frequency of adverse reactions was the following: gastrointestinal symptoms – 57.9 %, local symptoms – 65.8 %, cerebral symptoms – 46.8 %, fatigue – 54.4 %; signs of sialoadenitis six months after radioiodine therapy – 25.2 %. TT genotype carriers of ATG10 rs1864183 had higher frequency of gastrointestinal symptoms (vs. CC+CT), the CC genotype carriers of ATG10 rs10514231 had significantly more frequent cerebral symptoms (vs. CT+TT), as well as AA genotype carriers of TGFB1 rs1800469 (vs. AG+GG). CC genotype of ATG10 rs10514231 increased the incidence of radioiodine-induced fatigue, whereas GA genotype of the ATM rs11212570 had a protective role against fatigue. TGFB1 rs1800469 was associated with signs of sialoadenitis six months after radioiodine therapy.
Conclusions
Genetic factors may contribute to the occurrence of adverse reactions of radioiodine therapy in thyroid cancer patients.
-
Research funding: This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2022-301).
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the local ethics committee of Russian Medical Academy of Continuous Professional Education (9th February, 2021).
References
1. Haddad, RI, Bischoff, L, Ball, D, Bernet, V, Blomain, E, Busaidy, NL, et al.. Thyroid carcinoma, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2022;20:925–51. https://doi.org/10.6004/jnccn.2022.0040.Search in Google Scholar PubMed
2. Smanik, PA, Liu, Q, Furminger, TL, Ryu, K, Xing, S, Mazzaferri, EL, et al.. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996;226:339–45. https://doi.org/10.1006/bbrc.1996.1358.Search in Google Scholar PubMed
3. Levy, O, De la Vieja, A, Carrasco, N. The Na+/I- symporter (NIS): recent advances. J Bioenerg Biomembr 1998;30:195–206. https://doi.org/10.1023/a:1020577426732.10.1023/A:1020577426732Search in Google Scholar PubMed
4. Solans, R, Bosch, JA, Galofré, P, Porta, F, Roselló, J, Selva-O’Callagan, A, et al.. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001;42:738–43.Search in Google Scholar
5. Chung, J-K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002;43:1188–200.Search in Google Scholar
6. Spitzweg, C, Joba, W, Schriever, K, Goellner, JR, Morris, JC, Heufelder, AE. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 1999;84:4178–84. https://doi.org/10.1210/jcem.84.11.6117.Search in Google Scholar PubMed
7. Zeraatpishe, A, Oryan, S, Bagheri, MH, Pilevarian, AA, Malekirad, AA, Baeeri, M, et al.. Effects of Melissa officinalis L. on oxidative status and DNA damage in subjects exposed to long-term low-dose ionizing radiation. Toxicol Ind Health 2011;27:205–12. https://doi.org/10.1177/0748233710383889.Search in Google Scholar PubMed
8. Baum, BJ. Principles of saliva secretion. Ann N Y Acad Sci 1993;694:17–23. https://doi.org/10.1111/j.1749-6632.1993.tb18338.x.Search in Google Scholar PubMed
9. Kutta, H, Kampen, U, Sagowski, C, Brenner, W, Bohuslavizki, K-H, Paulsen, F. Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings. Strahlenther Onkol 2005;181:237–45. https://doi.org/10.1007/s00066-005-1353-3.Search in Google Scholar PubMed
10. Silberstein, EB. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med 2008;49:546–9. https://doi.org/10.2967/jnumed.107.049411.Search in Google Scholar PubMed
11. Hoelzer, S, Steiner, D, Bauer, R, Reiners, C, Farahati, J, Hundahl, SA, et al.. Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany. Eur J Nucl Med 2000;27:1465–72. https://doi.org/10.1007/s002590000333.Search in Google Scholar PubMed
12. Kielbassa, AM, Hinkelbein, W, Hellwig, E, Meyer-Lückel, H. Radiation-related damage to dentition. Lancet Oncol 2006;7:326–35. https://doi.org/10.1016/s1470-2045(06)70658-1.Search in Google Scholar PubMed
13. Dardano, A, Ballardin, M, Ferdeghini, M, Lazzeri, E, Traino, C, Caraccio, N, et al.. Anticlastogenic effect of Ginkgo biloba extract in Graves’ disease patients receiving radioiodine therapy. J Clin Endocrinol Metab 2007;92:4286–9. https://doi.org/10.1210/jc.2007-0597.Search in Google Scholar PubMed
14. Hernández-Jardines, A, Molina, B, del Castillo, V, Papadakis, M, Rivera, T, Azorín, J, et al.. Detection of short-term chromosomal damage due to therapeutic 131I exposure in patients with thyroid cancer. Rev Invest Clin 2010;62:31–8.Search in Google Scholar
15. Iarmarcovai, G, Ceppi, M, Botta, A, Orsière, T, Bonassi, S. Micronuclei frequency in peripheral blood lymphocytes of cancer patients: a meta-analysis. Mutat Res 2008;659:274–83. https://doi.org/10.1016/j.mrrev.2008.05.006.Search in Google Scholar PubMed
16. Van Nostrand, D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 2009;19:1381–91. https://doi.org/10.1089/thy.2009.1611.Search in Google Scholar PubMed
17. Luster, M, Clarke, SE, Dietlein, M, Lassmann, M, Lind, P, Oyen, WJG, et al.. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941–59. https://doi.org/10.1007/s00259-008-0883-1.Search in Google Scholar PubMed
18. Mandel, SJ, Mandel, L. Radioactive iodine and the salivary glands. Thyroid 2003;13:265–71. https://doi.org/10.1089/105072503321582060.Search in Google Scholar PubMed
19. Rubino, C, de Vathaire, F, Dottorini, ME, Hall, P, Schvartz, C, Couette, JE, et al.. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638–44. https://doi.org/10.1038/sj.bjc.6601319.Search in Google Scholar PubMed PubMed Central
20. Bourguignon, MH, Gisone, PA, Perez, MR, Michelin, S, Dubner, D, Giorgio, MDi, et al.. Genetic and epigenetic features in radiation sensitivity. Part II: implications for clinical practice and radiation protection. Eur J Nucl Med Mol Imaging 2005;32:351–68. https://doi.org/10.1007/s00259-004-1731-6.Search in Google Scholar PubMed
21. Jackson, SP, Bartek, J. The DNA-damage response in human biology and disease. Nature 2009;461:1071–8. https://doi.org/10.1038/nature08467.Search in Google Scholar PubMed PubMed Central
22. Fei, P, El-Deiry, WS. P53 and radiation responses. Oncogene 2003;22:5774–83. https://doi.org/10.1038/sj.onc.1206677.Search in Google Scholar PubMed
23. Jackson, SP. DNA-dependent protein kinase. Int J Biochem Cell Biol 1997;29:935–8. https://doi.org/10.1016/s1357-2725(97)00006-x.Search in Google Scholar PubMed
24. Tibbetts, RS, Brumbaugh, KM, Williams, JM, Sarkaria, JN, Cliby, WA, Shieh, SY, et al.. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999;13:152–7. https://doi.org/10.1101/gad.13.2.152.Search in Google Scholar PubMed PubMed Central
25. Shiloh, Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001;11:71–7. https://doi.org/10.1016/s0959-437x(00)00159-3.Search in Google Scholar PubMed
26. Kastan, MB, Lim, DS, Kim, ST, Yang, D. ATM--a key determinant of multiple cellular responses to irradiation. Acta Oncol 2001;40:686–8. https://doi.org/10.1080/02841860152619089.Search in Google Scholar PubMed
27. Hickson, I, Zhao, Y, Richardson, CJ, Green, SJ, Martin, NMB, Orr, AI, et al.. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152–9. https://doi.org/10.1158/0008-5472.can-04-2727.Search in Google Scholar
28. Singh, K, Matsuyama, S, Drazba, JA, Almasan, A. Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy 2012;8:236–51. https://doi.org/10.4161/auto.8.2.18600.Search in Google Scholar PubMed PubMed Central
29. Cortez, D, Guntuku, S, Qin, J, Elledge, SJ. ATR and ATRIP: partners in checkpoint signaling. Science 2001;294:1713–6. https://doi.org/10.1126/science.1065521.Search in Google Scholar PubMed
30. Singh, R, Shankar, BS, Sainis, KB. TGF-β1-ROS-ATM-CREB signaling axis in macrophage mediated migration of human breast cancer MCF7 cells. Cell Signal 2014;26:1604–15. https://doi.org/10.1016/j.cellsig.2014.03.028.Search in Google Scholar PubMed
31. Levine, AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–31. https://doi.org/10.1016/s0092-8674(00)81871-1.Search in Google Scholar PubMed
32. Ko, LJ, Prives, C. p53: puzzle and paradigm. Genes Dev 1996;10:1054–72. https://doi.org/10.1101/gad.10.9.1054.Search in Google Scholar PubMed
33. Thomasova, D, Mulay, SR, Bruns, H, Anders, H-J. p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia 2012;14:1097–101. https://doi.org/10.1593/neo.121534.Search in Google Scholar PubMed PubMed Central
34. Aggarwal, BB, Sung, B. NF-κB in cancer: a matter of life and death. Cancer Discov 2011;1:469–71. https://doi.org/10.1158/2159-8290.cd-11-0260.Search in Google Scholar PubMed PubMed Central
35. Bauerle, KT, Schweppe, RE, Haugen, BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer 2010;9:117. https://doi.org/10.1186/1476-4598-9-117.Search in Google Scholar PubMed PubMed Central
36. Chen, F, Yin, S, Zhu, J, Jia, L, Zhang, H, Yang, C, et al.. Effects of nuclear factor-κB on the uptake of 131iodine and apoptosis of thyroid carcinoma cells. Mol Med Rep 2018;17:4959–64. https://doi.org/10.3892/mmr.2018.8481.Search in Google Scholar PubMed PubMed Central
37. Yan, HQ, Zhang, D, Shi, YY, You, X, Shi, L, Li, Q, et al.. Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells. Oncotarget 2016;7:62070–83. https://doi.org/10.18632/oncotarget.11386.Search in Google Scholar PubMed PubMed Central
38. Katayama, M, Kawaguchi, T, Berger, MS, Pieper, RO. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 2007;14:548–58. https://doi.org/10.1038/sj.cdd.4402030.Search in Google Scholar PubMed
39. Dyavaiah, M, Rooney, JP, Chittur, SV, Lin, Q, Begley, TJ. Autophagy-dependent regulation of the DNA damage response protein ribonucleotide reductase 1. Mol Cancer Res 2011;9:462–75. https://doi.org/10.1158/1541-7786.mcr-10-0473.Search in Google Scholar
40. Liu, J, Tang, X, Shi, F, Li, C, Zhang, K, Liu, J, et al.. Genetic polymorphism contributes to 131 I radiotherapy-induced toxicities in patients with differentiated thyroid cancer. Pharmacogenomics 2018;19:1335–44. https://doi.org/10.2217/pgs-2018-0070.Search in Google Scholar PubMed
41. Yang, Z, Liu, Z. Potentially functional variants of autophagy‐related genes are associated with the efficacy and toxicity of radiotherapy in patients with nasopharyngeal carcinoma. Mol Genet Genomic Med 2019;7:1–8. https://doi.org/10.1002/mgg3.1030.Search in Google Scholar PubMed PubMed Central
42. Naranjo, CA, Busto, U, Sellers, EM, Sandor, P, Ruiz, I, Roberts, EA, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45. https://doi.org/10.1038/clpt.1981.154.Search in Google Scholar PubMed
43. Paillahueque Velásquez, G. Efectos secundarios a corto y mediano plazo del tratamiento con 131I en pacientes con cáncer diferenciado de tiroides. Santiago: Universidad de Chile; 2018. Available from: https://repositorio.uchile.cl/handle/2250/149434.Search in Google Scholar
44. Ordúz, S, Lisen, O. Incidencia de los efectos adversos tempranos y evaluación de calidad de vida en los pacientes que reciben terapia con radioyodo para el tratamiento del cáncer de tiroides en un servicio de referencia de medicina nuclear en Colombia. Bucaramanga: Universidad autónoma de bucaramanga; 2019. Available from: http://hdl.handle.net/20.500.12749/7219.Search in Google Scholar
45. Van Nostrand, D, Freitas, J. Side effects of 131I for ablation and treatment of well-differentiated thyroid carcinoma. In: Thyroid cancer. Totowa, NJ: Humana Press; 2006. p. 459–83. Available from: http://link.springer.com/10.1007/978-1-59259-995-0_52.10.1007/978-1-59259-995-0_52Search in Google Scholar
46. Hyer, S, Kong, A, Pratt, B, Harmer, C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol 2007;19:83–6. https://doi.org/10.1016/j.clon.2006.11.005.Search in Google Scholar PubMed
47. Burmeister, LA, du Cret, RP, Mariash, CN. Local reactions to radioiodine in the treatment of thyroid cancer. Am J Med 1991;90:217–22. https://doi.org/10.1016/0002-9343(91)90545-9.Search in Google Scholar
48. Denisenko, NP, Shuev, GN, Mukhamadiev, RH, Perfilieva, OM, Kazakov, RE, Kachanova, AA, et al.. Genetic markers associated with resistance to radioiodine therapy in thyroid cancer patients: prospective cohort study. J Mod Oncol 2022;24:345–50. Available from: https://modernonco.orscience.ru/1815-1434/article/view/110799. https://doi.org/10.26442/18151434.2022.3.201867.Search in Google Scholar
Supplementary Material
This article contains supplementary material (https://doi.org/10.1515/dmpt-2023-0007).
© 2023 Walter de Gruyter GmbH, Berlin/Boston
